Clinical trial
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo +…
NCT00567190 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00567190 |
|---|---|
| Title | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer |
| Acronym | CLEOPATRA |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Pertuzumab, Placebo, Trastuzumab, Docetaxel |
| Enrollment | 808 |
| Start date | Feb 12, 2008 |
| Primary completion | May 13, 2011 |
| Completion | Nov 23, 2018 |
| First posted | Dec 4, 2007 |
| Last update posted | Dec 13, 2019 |
| Countries | Argentina, Brazil, Canada, China, Costa Rica, Croatia, Ecuador, Finland, France, Germany, Guatemala, Hong Kong and 14 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: